← Leaderboards
Paul M. Mathews
Nathan S. Kline Institute For Psych Res
$7,108,613
Attributed
$10,779,291
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,779,291 · 8
By mechanism
RF1$4,874,000 · 2
P01$3,164,796 · 2
R01$1,055,283 · 1
R61$810,596 · 1
R56$595,009 · 1
R21$279,607 · 1
Top collaborators
- Efrat Levy3 shared
- Donald A Wilson2 shared
- Stephen D. Ginsberg1 shared
- Martin Joseph Sadowski1 shared
- David Minh Truong1 shared
Most similar at Nathan S. Kline Institute For Psych Res
Same institution · by research overlap
- Stephen D. Ginsberg$17,729,760
- Yasuji Matsuoka$870,125
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposNeuronsCellsMediatingIn VivoBrainPathologyS DiseasePathway InteractionsEventLinkIn VitroGenotypeRecyclingApolipoprotein EEndosomesCholesterolPhenotypeNerve DegenerationPlayEarly EndosomeApolipoprotein E-4Functional DisorderLead
Grant awards (21)
Off-the-shelf CAR-Engineered Macrophage Therapy for Alzheimerâs Disease$810,596
R61 · FY2025 · AG
Apolipoprotein E genotype modulates brain mitovesicle production, a component of mitochondrial quality control$2,499,343
RF1 · FY2024 · AG
Modulation of endosomal pathway dysfunction in Alzheimer's disease$292,712
P01 · FY2021 · AG · contact PI
Modulation of endosomal pathway dysfunction in Alzheimer's disease$292,712
P01 · FY2020 · AG · contact PI
Neuronal Protective Apolipoprotein E2-mediated endocytic and exocytic pathways$249,884
RF1 · FY2020 · AG
Modulation of endosomal pathway dysfunction in Alzheimer's disease$292,711
P01 · FY2019 · AG · contact PI
Pathogenic consequences of altered insulin signaling in the diabetic brain.$595,009
R56 · FY2018 · AG · contact PI
Modulation of endosomal pathway dysfunction in Alzheimer's disease$292,711
P01 · FY2018 · AG · contact PI
Neuronal Protective Apolipoprotein E2-mediated endocytic and exocytic pathways$2,124,773
RF1 · FY2017 · AG
Modulation of endosomal pathway dysfunction in Alzheimer's disease$290,250
P01 · FY2017 · AG · contact PI
THE ORIGINS OF ENDOSOME DYSFUNCTION IN AD PATHOBIOLOGY$417,011
P01 · FY2009 · AG · contact PI
THE ORIGINS OF ENDOSOME DYSFUNCTION IN AD PATHOBIOLOGY$375,840
P01 · FY2008 · AG · contact PI
THE ORIGINS OF ENDOSOME DYSFUNCTION IN AD PATHOBIOLOGY$332,690
P01 · FY2007 · AG · contact PI
Calpain Regulation of Amyloid-beta and Plaque Formation$258,568
R01 · FY2007 · NS · contact PI
THE ORIGINS OF ENDOSOME DYSFUNCTION IN AD PATHOBIOLOGY$293,351
P01 · FY2006 · AG · contact PI
Calpain Regulation of Amyloid-beta and Plague Formation$263,796
R01 · FY2006 · NS · contact PI
THE ORIGINS OF ENDOSOME DYSFUNCTION IN AD PATHOBIOLOGY$284,808
P01 · FY2005 · AG
Calpain Regulation of Amyloid-beta and Plague Formation$267,663
R01 · FY2005 · NS
Calpain Regulation of Amyloid-beta and Plaque Formation$265,256
R01 · FY2004 · NS
Cell-based screens for Alzheimer's disease therapeutics$140,767
R21 · FY2004 · NS
Cell-based screens for Alzheimer's disease therapeutics$138,840
R21 · FY2003 · NS